Results 61 to 70 of about 2,777,517 (335)

Immunological Treatments for Occupational Allergy [PDF]

International Journal of Immunopathology and Pharmacology, 2013
Although avoidance of occupational triggers remains the primary step in the management of work-related allergies, immunological treatments (including biological agents and specific immunotherapy) can be regarded as potential therapeutic options for IgE-mediated diseases; for example, many studies with allergen-specific immunotherapy have been carried ...
Crivellaro, M., Senna, G., Marcer, G., PASSALACQUA, GIOVANNI   +3 more
openaire   +5 more sources

Priority Musculoskeletal Health Research Questions for People With Generalized Joint Hypermobility: An International Delphi Study

Arthritis Care &Research, EarlyView.
Objective This study aimed to identify the top 10 international research priorities for musculoskeletal health of people with generalized joint hypermobility. Methods A three‐round Delphi method using an online survey was implemented. Three participant stakeholder groups were eligible for inclusion: (1) people with lived experience of joint ...
Sara Habibian, Verity Pacey, Cliffton Chan, Alan J. Hakim, Cylie M. Williams   +4 more
wiley   +1 more source

Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT

American Journal of Hematology, Volume 98, Issue 1, Page 112-121, January 2023., 2023
Abstract Following the introduction of tyrosine kinase inhibitors (TKI), the number of patients undergoing allogeneic hematopoietic cell transplantation (allo‐HCT) for chronic phase (CP) chronic myeloid leukemia (CML) has dramatically decreased. Imatinib was the first TKI introduced to the clinical arena, predominantly utilized in the first line ...
Yves Chalandon, Giulia Sbianchi, Luuk Gras, Linda Koster, Jane Apperley, Jenny Byrne, Urpu Salmenniemi, Henrik Sengeloev, Mahmoud Aljurf, Grzegorz Helbig, Francesca Kinsella, Goda Choi, Péter Reményi, John A. Snowden, Marie Robin, Stig Lenhoff, Stephan Mielke, Jakob Passweg, Annoek E. C. Broers, Nicolaus Kröger, Zeynep Arzu Yegin, Sen Mui Tan, Patrick J. Hayden, Donal P. McLornan, Ibrahim Yakoub‐Agha, on behalf of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT)   +25 more
wiley   +1 more source

Pregnancy Outcomes of Targeted Synthetic Disease‐Modifying Antirheumatic Drugs Among Patients With Autoimmune Diseases: A Scoping Review

Arthritis Care &Research, EarlyView.
Objective Targeted synthetic disease‐modifying antirheumatic drugs (tsDMARDs) have expanded the management of autoimmune diseases, including rheumatic diseases. As the use of these drugs grows, it is important to understand their effects on pregnancy.
Vienna Cheng, Neda Amiri, Vicki Cheng, Ursula Ellis, Jacquelyn J. Cragg, Mark Harrison, Laurie Proulx, Mary A. De Vera   +7 more
wiley   +1 more source

Utilization of real‐world data in assessing treatment effectiveness for diffuse large B‐cell lymphoma

American Journal of Hematology, Volume 98, Issue 1, Page 180-192, January 2023., 2023
Abstract Direct comparisons of the effectiveness of the numerous novel therapies in the diffuse large B‐cell lymphoma (DLBCL) treatment landscape in a range of head‐to‐head randomized phase 3 trials would be time‐consuming and costly. Comparative effectiveness studies using real‐world data (RWD) represent a complementary approach.
Grzegorz Nowakowski, Matthew J. Maurer, James R. Cerhan, Debarshi Dey, Laurie H. Sehn   +4 more
wiley   +1 more source

Chlorhexidine Allergy: Current Challenges and Future Prospects

Journal of Asthma and Allergy, 2020
Chirawat Chiewchalermsri,1,2 Mongkhon Sompornrattanaphan,3 Chamard Wongsa,3 Torpong Thongngarm3 1Division of Allergy and Clinical Immunology, Department of Medicine, Phramongkutklao Hospital, Bangkok, Thailand; 2Department of Medicine, Panyananthaphikkhu
Chiewchalermsri C, Sompornrattanaphan M, Wongsa C, Thongngarm T   +3 more
doaj  

An introduction to the immune network [PDF]

arXiv, 1995
In this paper, after a telegraphic introduction to modern immunology, we present a simple model for the idiotypic network among antibodies and we study its relevance for the maintenance of immunological memory. We also consider the problem of computing the memory capacity of such a model.
arxiv  

Effects of Pharmacologic and Nonpharmacologic Interventions for the Management of Sleep Problems in People With Fibromyalgia: Systematic Review and Network Meta‐Analysis of Randomized Controlled Trials

Arthritis Care &Research, EarlyView.
Objective Fibromyalgia is a chronic condition characterized by widespread musculoskeletal pain and fatigue. Almost everyone with fibromyalgia has sleep problems. We aimed to evaluate the effectiveness and safety of current interventions for the management of fibromyalgia‐related sleep problems.
Jemma Hudson, Mari Imamura, Clare Robertson, Daniel Whibley, Lorna Aucott, Katie Gillies, Paul Manson, Debra Dulake, Abhishek Abhishek, Nicole K. Y. Tang, Gary J. Macfarlane, Miriam Brazzelli   +11 more
wiley   +1 more source

Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis

, 2023
American Journal of Hematology, Volume 98, Issue 1, Page E15-E19, January 2023.
Meletios A. Dimopoulos, Philippe Moreau, Bradley Augustson, Nelson Castro, Tomas Pika, Sosana Delimpasi, Javier De la Rubia, Angelo Maiolino, Tony Reiman, Joaquin Martinez‐Lopez, Thomas Martin, Joseph Mikhael, Kwee Yong, Marie‐Laure Risse, Gaelle Asset, Sylvia Marion, Roman Hajek   +16 more
wiley   +1 more source

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes

American Journal of Hematology, Volume 98, Issue 2, Page 272-281, February 2023., 2023
Abstract Patients with relapsed/refractory (R/R) higher‐risk myelodysplastic syndromes (MDS) have a dismal median overall survival (OS) after failing hypomethylating agent (HMA) treatment. There is no standard of care for patients after HMA therapy failure; hence, there is a critical need for effective therapeutic strategies.
Amer M. Zeidan, Uma Borate, Daniel A. Pollyea, Andrew M. Brunner, Fernando Roncolato, Jacqueline S. Garcia, Robin Filshie, Olatoyosi Odenike, Anne Marie Watson, Ravitharan Krishnadasan, Ashish Bajel, Kiran Naqvi, Jiuhong Zha, Wei‐Han Cheng, Ying Zhou, David Hoffman, Jason G. Harb, Jalaja Potluri, Guillermo Garcia‐Manero   +18 more
wiley   +1 more source